| CAS NO: | 301326-22-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 333.39 |
|---|---|
| Formula | C19H19N5O |
| CAS No. | 301326-22-7 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 66 mg/mL (198.0 mM) |
| Water: <1 mg/mL | |
| Ethanol: 4 mg/mL (12.0 mM) | |
| SMILES Code | O=C(C1=CC=NN1C)NC2=CC=C(/N=N/C3=CC=CC=C3C)C=C2C |
| Synonyms | CH223191; CH-223191; CH 223191. |
| In Vitro | In vitro activity: CH-223191 blocks TCDD-mediated nuclear translocation and DNA binding of AhR, and also causes the inhibition of TCDD-induced cytochrome P450 enzyme activity. In human glioblastoma cells, CH-223191downregulates the TGF-beta/Smad pathway, and reduces clonogenic survival and invasiveness. In SK-N-SH human-derived neuronal cells, CH223191 counteracts the TCDD-induced suppression of neuronal acetylcholinesterase expression. In endothelial cells, CH-223191 potentiates ICAM-1 expression and prevents RelB nuclear translocation. |
|---|---|
| In Vivo | CH-223191 (10 mg/kg/day, p.o.) potently prevents TCDD-caused cytochrome P450 induction, liver toxicity, and wasting syndrome in mice. |
| Animal model | Male ICR mice |
| Formulation & Dosage | Dissolved in Coin oil; 10 mg/kg; p.o. |
| References | Mol Pharmacol. 2006 Jun;69(6):1871-8; Oncogene. 2009 Jul 16;28(28):2593-605. |
m.cnreagent.com